First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma
We present two cases of von Hippel–Lindau (VHL) disease-associated hemangioblastomas in the CNS treated with the newly approved HIF-2α inhibitor, belzutifan. The first case is a 31-year-old female with confirmed pathogenic germline VHL mutation who presented with multiple hemangioblastomas. The pati...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis Group
2022-09-01
|
| Schriftenreihe: | CNS Oncology |
| Schlagworte: | |
| Online-Zugang: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0008 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|